The Life Sciences team advised BridgeBio Pharma, Inc. (NASDAQ:BBIO) subsidiary Eidos Therapeautics, Inc. (NASDAQ:EIDX) on an agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan. AG10 is a small molecule designed to treat the root cause of transthyretin amyloidosis (ATTR) – destabilized and misfolded transthyretin (TTR) protein – by binding and stabilizing TTR in the blood.
BridgeBio is a company of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. Its subsidiary Eidos is focused on addressing the large and growing unmet need in diseases caused by ATTR.
Eidos is currently evaluating AG10 in a Phase 3 study in the U.S. and Europe for ATTR cardiomyopathy (ATTR-CM) – a progressive, fatal disease caused by the accumulation of misfolded TTR amyloid in the heart – and plans to begin a Phase 3 study in ATTR polyneuropathy (ATTR-PN) – a progressive, fatal disease caused by the accumulation of misfolded TTR amyloid in the peripheral nervous system.
Under the terms of the agreement, global biopharmaceutical company Alexion will acquire an exclusive license for the clinical development and commercialization of AG10 in Japan. Eidos will receive an upfront payment of $25 million and received an equity investment of $25 million at a premium to the market price upon deal execution, with the potential for additional Japanese-based milestone- and royalty-dependent payments.
The Goodwin team was led by partners Noelle Dubiansky and Maggie Wong, and included partner Robert Carroll and associates Emily Beman, Eugene Shin, Shoaib Ghias, Alexander Varond and Jonathan LaPlante.